Regular use of aspirin might help protect some people against developing cancer, researchers say today.
The effect of the pill on cancer risk is small – but it can last for several years after someone stops taking it, according to a new analysis.
Experts said "important questions" remain before anyone can be advised to take the pill to prevent cancer.
A new study has assessed all the available evidence on using aspirin as a preventive measure.
Daily aspirin appears to reduce the risk of heart disease, and evidence is growing that it may also help prevent cancer. It also carries a risk of gastrointestinal bleeding and peptic ulcer, so its benefits must be balanced against its harms, the researchers warn.
The team reviewed several reliable studies and found: "The effects of aspirin on cancer are not apparent until at least three years after the start of use, and some benefits are sustained for several years after cessation in long-term users."
They saw no clear differences between high, low and standard doses of aspirin. Excess bleeding was the biggest risk, with risk and fatality rate increasing with age.
In the Annals of Oncology today (6 August) they write: "For average-risk individuals aged 50 to 65 years taking aspirin for ten years, there would be a relative reduction of 7% for women and 9% for men in the number of cancer, heart attack or stroke events over a 15-year period and an overall 4% relative reduction in all deaths over a 20-year period."
The team, led by Professor Jack Cuzick of Queen Mary University of London, UK, call for further work to determine the best dose and duration of use. It would also be helpful to have a method of identifying those at increased risk of bleeding, they say.
Dr Julie Sharp, from Cancer Research UK, said the pill showed "promise" in preventing some kinds of cancer.
She said: "Before aspirin can be recommended for cancer prevention some important questions need to be answered, including what is the best dose and how long people should take it for. And tests need to be developed to predict who is likely to have side effects."
Cuzick, J. et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Annals of Oncology 6 August 2014 doi:10.1093/annonc/mdu225

Leave a Reply